orthovita+60% UMSATZSTEIGERUNG - 500 Beiträge pro Seite

[jacky06]

auf leisen sohlen macht sie ihren weg und keiner bekommt es so richtig mit.richtig so-zocker bleibt draussen!
ich vermuhte sogar,dass in der nächsten zeit noch eine grosses geschäft ansteht!wünsche uns allen viel spass mit orthovita /VITA/-914566- !!!

[jacky06]

Orthovita is a biomaterials company with proprietary technologies applied to the development of biostructures, synthetic biologically active tissue engineering products for restoration of the human skeleton. Our focus is on developing novel products for use in spine surgery and in the repair of osteoporotic fractures. We are also addressing a broad range of clinical needs in the trauma market.

We have applied our technologies to the development of several products, VITOSS(R) Synthetic Cancellous Bone Void Filler, CORTOSS(R) Synthetic Cortical Bone Void Filler and RHAKOSS(TM) Synthetic Bone Spinal Implant, that we believe offer a wide range of clinical applications at various anatomical sites. In addition, we are marketing IMBIBE(R) Bone Marrow Aspirate Syringe to be used with VITOSS, ALIQUOT(TM) Microdelivery System to be used with CORTOSS, and Endoskeleton(TM) to be used in the thoracolumbar spine to replace all or part of a collapsed, damaged or unstable vertebral body due to trauma or tumor.

Orthovita also pursues opportunities to work jointly with other leaders in biomaterials research and product development. Orthovita established a collaboration with Kensey Nash Corporation (NASDAQ:KNSY) to commercialize new products based on Orthovita`s proprietary, ultra porous VITOSS bone void filler material in combination with proprietary Kensey Nash biomaterials. The new products to be developed under this collaboration are expected to broaden the spectrum of options available to our surgeon customers and enhance the deliverability of our VITOSS product line.

VITOSS is a resorbable calcium phosphate scaffold that is highly porous and composed of extremely fine calcium phosphate mineral that allows for resorption, cell seeding and ingrowth of host bone. VITOSS is cleared for sale in the U.S. and Australia, and approved for sale under a CE Mark in Europe.

CORTOSS is a high-strength, self-setting composite engineered specifically to mimic the strength characteristics of human cortical bone. CORTOSS is cleared for sale in Australia and is approved for sale under a CE Mark in Europe for use in screw augmentation and vertebral augmentation procedures including compression fractures caused by osteoporosis and invasive tumors. CORTOSS is not available for commercial distribution in the U.S. We are conducting clinical studies of CORTOSS required for approval in the U.S. for use in vertebral augmentation procedures. In addition, we completed post-marketing human clinical studies of CORTOSS in Europe for its use in hip compression screw augmentation.

RHAKOSS is under development in Europe as a preformed composite that mimics the natural dual cortical-cancellous composition of human bone, providing high strength while also allowing for the ingrowth of host bone to address the vertebral interbody fusion and spinal reconstruction market. We are conducting clinical studies of RHAKOSS in Europe required to obtain a CE Mark for its use as an interbody fusion device.

This press release contains forward-looking statements regarding our current expectations of future events that involve risks and uncertainties, including without limitations, our VITOSS, CORTOSS and RHAKOSS products and other aspects of our business. Such statements are based on our current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, our dependence on the commercial success of our approved products, our history of operating losses and our need for additional funds, our need to obtain and maintain regulatory approvals to sell our products, the rate at which we invest in our field sales network, the ability of our field sales network to generate new sales, our ability to enter into an agreement to commercialize and distribute VITOSS in Japan, our ability to manage commercial scale manufacturing capability and capacity, risks and uncertainties in pre-clinical and clinical trial results, market acceptance of our products, the sales levels of our products, research and development, competition and other risk factors listed from time to time in reports filed by the Company with the Securities and Exchange Commission, including but not limited to risks described in our most recently filed Form 10-K under the caption " Certain Risks Related to Our Business." Further information about these and other relevant risks and uncertainties may be found in Orthovita`s filings with the Commission, all of which are available from the Commission as well as other sources. Orthovita undertakes no obligation to publicly update any forward-looking statements.

SOURCE: Orthovita, Inc.

[jacky06]

--------------------------------------------------------------------------------

4investors Nanotech-Letter - Ausgabe Mai 2004
Analysen zu NVE, Nanogen und SkyePharma - dazu Kurzupdates und ausführliche Statistiken!


Die aktuelle Ausgabe des 4investors Nanotech-Letter können Sie hier herunterladen!

Aktuelle Analysen zu NVE, Nanogen und SkyePharma - dazu kurze Analyseupdates zu Biosante, Flamel, Orthovita und Veeco sowie eine ausführliche Nanotechaktien-Statistik!

Editorial:
Mit Schwung und viel Zuspruch von Ihrer Seite startete mit der April-Ausgabe unser neues Informationsangebot, der 4investors Nanotech-Letter. Wir widmen uns damit als einer der Ersten regelmäßig einer Branche, die zurecht die Hoffnung auf eine revolutionäre Entwicklung in den kommenden Jahrzehnten in sich trägt.

Vielfach werden die Nanotechnologie-Aktien mit Internet-Werten vor dem Boom verglichen. Ich sehe das nicht so. Zum einen ist das Know-How beider Branchen kaum vergleichbar, im Nanotech-Bereich ungleich höher als im Internet. Das bedeutet wesentlich höhere Markteintrittsbarrieren und weniger Konkurrenz, vor allem wo regulatorische Hindernisse wie zum Beispiel im Nano-Pharmasektor, zu überwinden sind.

Allerdings zeigt sich die Branche auch noch erwachsener als das Internet. Ein großer Teil der Unternehmen mit Nanotech-Phantasie sind alte Bekannte: Siemens gehört zum Beispiel dazu, viele Chipwerte, oder auch der SDAX-Wert Masterflex, um nur einige deutsche Vertreter zu nennen.

Der Vorteil: Die Branche startet von einer anderen fundamentalen Basis aus als das Internet. Viele Werte, wie der Blick in unseren Fundamental-Statistikteil ab Seite 5 zeigt, schreiben bereits Gewinne - zwar oftmals mit anderen als nanotechnologischen Produkten erzielt, dennoch mit viel Phantasie für die Zukunft ausgestattet. Gute Voraussetzungen, dass der Trend nicht im Sande versickert.

Die aktuelle Ausgabe des 4investors Nanotech-Letter können Sie hier herunterladen!

Inhaltsverzeichnis:
Analyse: NVE Corp.
Analyse: Nanogen
Analyse: Skye Pharma
Nachrichten und Kurzanalysen zu Biosante, Flamel, Orthovita und Veeco
Nanotechnologie-Aktien im Fundamental-Check

Die aktuelle Ausgabe des 4investors Nanotech-Letter können Sie hier herunterladen!

[a.l.e.x.]

Hi,

kommst Du an die Infos über Orthovita dran?

Gruß